Advanced Cell Technology, Inc. , a leader in the field of regenerative ophthalmology, announced today that it has completed treatment of the final patient in its U.K. based Phase 1 clinical trial for Stargardt's macular degeneration . The successful transplantation of the Company's proprietary RPE cells in the last patient of twelve represents the completion of the enrollment stage of this trial.
http://ift.tt/YaEqvy
http://ift.tt/YaEqvy
No comments:
Post a Comment